SEC Form 4 · accession 0001192482-18-000161
Zynerba Pharmaceuticals, Inc. · ZYNE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John P. Butler
Director
Period of report
Apr 12, 2018
Accepted (ET)
Apr 16, 2018 · 4:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001621443
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $9.90 | Apr 12, 2018 | A | 35,000 | A | Apr 12, 2018 | Apr 12, 2028 | Common Stock | 35,000 | 35,000 | D |
Explanation of responses
- F1The option vests in three equal installments on April 12, 2019, 2020, and 2021.